Acne in recipients of renal transplantation treated with sirolimus: Clinical, microbiologic, histologic, therapeutic, and pathogenic aspects

Journal of the American Academy of Dermatology

Volumn 55, Issue 1, 2006, Pages 139-142

  Mahé, Emmanuel ^a,c   Morelon, Emmanuel ^b,d   Lechaton, Sophie ^b   Drappier, Jean Christophe ^a   de Prost, Yves ^a   Kreis, Henri ^b   Bodemer, Christine ^a  

^a Departments of Dermatology   (France)

^b Necker Enfants Malades University Hospital   (United States)

^c Bichat Claude Bernard University Hospital   (United States)

^d EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR; RAPAMYCIN;

ACNE; ACNE VULGARIS; ARTICLE; BACTERIOLOGY; CLINICAL FEATURE; FEMALE; HISTOLOGY; HUMAN; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ACNE VULGARIS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; SIROLIMUS;

EID: 33745006874     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2005.11.1072     Document Type: Article

References (23)

1. Saunders R.N., Metcalfe M.S., and Nicholson M.L. Rapamycin in transplantation: a review of the evidence. Kidney Int 59 (2001) 3-16
2. Groth C.G., Backman L., Morales J.M., Calne R., Kreis H., Lang P., et al. Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine; sirolimus European renal transplant study group. Transplantation 67 (1999) 1036-1042
3. Kahan B.D. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomized multicenter study: the Rapamune US study group. Lancet 356 (2000) 194-202
4. MacDonald A.S., and Rapamune Global Study Group. A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation 71 (2001) 271-280
5. Van Hooff J.P., Squifflet J.P., Wlodarczyk Z., Vanrenterghem Y., and Paczek L. A prospective randomized multicenter study of tacrolimus in combination with sirolimus in renal-transplant recipients. Transplantation 75 (2003) 1934-1939
6. Morelon E., and Kreis H. Sirolimus therapy without calcineurin inhibitors: Necker Hospital 8-year experience. Transplant Proc 35 Suppl (2003) S52-S57
7. MacDonald A.S. Rapamycin in combination with cyclosporine or tacrolimus in liver, pancreas, and kidney transplantation. Transplant Proc 35 Suppl (2003) S201-S208
8. Kreis H., Oberbauer R., Campistol J.M., Mathew T., Daloze P., Schena F.P., et al. Long-term benefits with sirolimus-based therapy after early cyclosporine withdrawal. J Am Soc Nephrol 15 (2004) 809-817
9. Reitamo S., Spuls P., Sassolas B., Lahfa M., Claudy A., and Griffiths C.E. Efficacy of sirolimus (rapamycin) administered concomitantly with a subtherapeutic dose of cyclosporin in the treatment of severe psoriasis: a randomized controlled trial. Br J Dermatol 145 (2001) 438-445
10. Nadiminti U., and Arbiser J.L. Rapamycin (sirolimus) as a steroid-sparing agent in dermatomyositis. J Am Acad Dermatol 52 Suppl (2005) 17-19
11. Migita K., Eguchi K., Aoyagi T., Kawabe Y., Tsukada T., Aoyagi T., et al. The effects of the immunosuppressant rapamycin on the growth of rheumatoid arthritis (RA) synovial fibroblasts. Clin Exp Immunol 104 (1996) 86-91
12. Van Gelder T., ter Meulen C.G., Hene R., Hene R., Weimar W., and Hoitsma A. Oral ulcers in kidney transplant recipients treated with sirolimus and mycophenolate mofetil. Transplantation 75 (2003) 788-791
13. Mohaupt M.G., Vogt B., and Frey F.J. Sirolimus-associated eyelid edema in kidney transplant recipients. Transplantation 72 (2001) 162-164
14. Aboujaoude W., Milgrom M.L., and Govani M.V. Lymphedema associated with sirolimus in renal transplant recipients. Transplantation 77 (2004) 1094-1096
15. Mahé E., Morelon E., Lechaton S., Le Quan Sang K.H., Mansouri R., Ducasse M.F., et al. Cutaneous adverse events in renal transplant recipients receiving sirolimus-based therapy. Transplantation 79 (2005) 476-482
16. Nomura M., He Z., Koyama I., Ma W.Y., Miyamoto K., and Dong Z. Involvement of the Akt/mTOR pathway on EGF-induced cell transformation. Mol Carcinog 38 (2003) 25-32
17. Busam K.J., Capodieci P., Motzer R., Kiehn T., Phelan D., and Halpern A.C. Cutaneous side effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br J Dermatol 144 (2001) 1169-1176
18. Lee M.W., Seo C.W., Kim S.W., Yang H.J., Lee H.W., and Choi J.H. Cutaneous side effects in non-small cell lung cancer patients treated with Iressa (ZD1839), an inhibitor of epidermal growth factor. Acta Derm Venereol 84 (2004) 23-26
19. Cohen M.H., Williams G.A., Sridhara R., Chen G., McGuinn Jr. W.D., Morse D., et al. United States Food and Drug Administration drug approval summary: gefitinib (ZD1839; Iressa) tablets. Clin Cancer Res 10 (2004) 1212-1218
20. Saltz L.B., Meropol N.J., Loehrer Sr. P.J., Needle M.N., Kopit J., and Mayer R.J. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22 (2004) 1201-1208
21. Noguchi S., Ohba Y., and Oka T. Pretranslational enhancement of epidermal growth factor receptor by direct effect of testosterone in mouse liver. Endocrinology 128 (1991) 2141-2148
22. Fritsche L., Budde K., Dragun D., Einecke G., Diekmann F., and Neumayer H.H. Testosterone concentrations and sirolimus in male renal transplant patients. Am J Transplant 4 (2004) 130-131
23. Tondolo V., Citterio F., Panocchia N., Nanni G., and Castagneto M. Sirolimus impairs improvement of the gonadal function after renal transplantation. Am J Transplant 5 (2005) 197